Extended Data Fig. 2: Elranatamab-induced changes in soluble BCMA.
From: Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
BCMA, B-cell maturation antigen; CR, complete response; MR, minimal response; PD, progressive disease; PR, partial response; QW, once weekly; sBCMA, soluble B-cell maturation antigen; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.
